Emmanuel Sevin

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2014 · 438 citations · Full text

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

Sylvie Négrier, Gwénaëlle Gravis, David Pérol et al. · The Lancet Oncology · 2011 · 236 citations

Urology, Genitourinary Cancer, Medicine +5

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2015 · 207 citations · Full text

Placebo-controlled Phase 3, Medicine, Metronomic Therapy +9

Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis

Sylvie Négrier, David Pérol, Alain Ravaud et al. · Cancer · 2007 · 181 citations · Full text

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)

Alain Ravaud, Stéphane Oudard, Marc de Fromont et al. · Annals of Oncology · 2015 · 153 citations · Full text

Type 1, French Genitourinary Group, Urology +6